# Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

> **NCT04251169** · PHASE2 · TERMINATED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 20 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04251169
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-21
- **Primary completion:** 2024-04-10
- **Final completion:** 2024-04-30
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The enrollment was stopped prematurely due to the lack of funding
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251169, "Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04251169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*